Xi Lin

Cargene Therapeutics

Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Using proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases. In December 2021, Cargene successfully closed an over-subscribed US$19.2 million pre-Series A funding round led by BioTrack Capital, with participation from Hyfinity Investments, Legendstar Capital and other renowned investors.